アッシャー症候群市場 - 市場の洞察、疫学、市場予測：2034年

アッシャー症候群（USH）は、聴覚と視覚の障害を併発する最も一般的な遺伝性疾患です。一部の症例では平衡障害や両側前庭反射も認められます。

病態生理学、疾患の重症度、結果に関する限られた知識が、アッシャー症候群に対する効果的な治療法の開発を妨げています。

アッシャー症候群の人は生まれつきですが、通常は子供か10代で診断されます。アッシャー症候群を治療する方法はありませんが、治療別視覚、聴覚、平衡感覚の問題を解決することができます。

主要7ヶ国の中で、2023年にアッシャー症候群の有病率が最も高かったのは米国で、約21,000例でした。

市場は、アッシャー症候群の根本原因に対処しない適応外療法に依存しています。患者は、ビタミン補助食品、日光保護、視覚補助などの支持療法に依存しています。現在、Luxturnaはアッシャー症候群の一般的な特徴である網膜変性に対して承認された唯一の治療薬です。

2023年、主要7ヶ国におけるアッシャー症候群の総市場規模は7,700万米ドルでした。

当レポートでは、主要7ヶ国におけるアッシャー症候群市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 主要な洞察

第2章 レポートのイントロダクション

第3章 アッシャー症候群（USH）のエグゼクティブサマリー

第4章 アッシャー症候群市場概要

• 主要7ヶ国におけるアッシャー症候群の市場シェア（%）分布、2020年、治療法別
• 主要7ヶ国におけるアッシャー症候群の市場シェア（%）分布、2034年、治療法別

第5章 主要な出来事

第6章 疫学と市場予測調査手法

第7章 アッシャー症候群：病気の背景と概要

• イントロダクション
• USHの遺伝学
• 予後
• 徴候と症状
• 病因
• 診断
• 治療管理

第8章 疫学と患者人口

• 主な調査結果
• 前提と根拠
• 主要7ヶ国におけるアッシャー症候群の有病者数の合計
• 米国
• EU4ヶ国と英国
• 日本

第9章 患者動向

第10章 上市済み薬剤

第11章 新興薬

第12章 アッシャー症候群：市場分析

• 主な調査結果
• 市場の見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7ヶ国のアッシャー症候群の総市場規模
• 米国の市場規模
• EU4ヶ国と英国の市場規模
• 日本の市場規模

第13章 アンメットニーズ

第14章 SWOT分析

第15章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本
• アッシャー症候群の市場アクセスと償還

第16章 付録

第17章 DEVEINSIGHTの機能

第18章 免責事項

第19章 DELVEINSIGHTについて

List of Tables

• Table 1: Summary of Usher Syndrome Market and Epidemiology (2020-2034)
• Table 2: Total Prevalent Cases of Usher Syndrome in the 7MM (2020-2034)
• Table 3: Total Prevalent Cases of Usher Syndrome in the US (2020-2034)
• Table 4: Type-specific Cases of Usher Syndrome in the US (2020-2034)
• Table 5: Total Prevalent Cases of Usher Syndrome in EU4 and the UK (2020-2034)
• Table 6: Type-specific Cases of Usher Syndrome in EU4 and the UK (2020-2034)
• Table 7: Total Prevalent Cases of Usher Syndrome in Japan (2020-2034)
• Table 8: Type-specific Cases of Usher Syndrome in Japan (2020-2034)
• Table 9: LUXTURNA, Clinical Trial Description
• Table 10: Comparison of Emerging Drugs
• Table 11: Ultevursen, Clinical Trial Description, 2023
• Table 12: NP1-001, Clinical Trial Description, 2023
• Table 13: Key Market Forecast Assumption of Usher Syndrome in the United States
• Table 14: Key Market Forecast Assumption of Usher Syndrome in EU4 and the UK
• Table 15: Key Market Forecast Assumption of Usher Syndrome in Japan
• Table 16: Total Market Size of Usher Syndrome in the 7MM, USD million (2020-2034)
• Table 17: Total Market Size of Usher Syndrome in the US, USD million (2020-2034)
• Table 18: Market Size of Usher Syndrome by Therapies in the US, USD million (2020-2034)
• Table 19: Total Market Size of Usher Syndrome in EU4 and the UK, USD million (2020-2034)
• Table 20: Market Size of Usher Syndrome by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 21: Total Market Size of Usher Syndrome in Japan, USD million (2020-2034)
• Table 22: Market Size of Usher Syndrome by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1: Schematic Representation of a Sensorineural Cell in the Inner Ear
• Figure 2: Schematic Representation of Structures, Genes, and Proteins Involved in USH. (A) Main Structures of a Sensorineural Inner Ear Cell. (B) Different Genes and Proteins are Responsible for Different USH Subtypes
• Figure 3: Flowchart for Investigation and Treatment of Bilateral Profound Sensorineural Hearing Loss
• Figure 4: Total Prevalent Cases of Usher Syndrome in the 7MM (2020-2034)
• Figure 5: Total Prevalent Cases of Usher Syndrome in the US (2020-2034)
• Figure 6: Type-specific Cases of Usher Syndrome in the US (2020-2034)
• Figure 7: Total Prevalent Cases of Usher Syndrome in EU4 and the UK (2020-2034)
• Figure 8: Type-specific Cases of Usher Syndrome in EU4 and the UK (2020-2034)
• Figure 9: Total Prevalent Cases of Usher Syndrome in Japan (2020-2034)
• Figure 10: Type-specific Cases of Usher Syndrome in Japan (2020-2034)
• Figure 11: Total Market Size of Usher Syndrome in the 7MM (2020-2034)
• Figure 12: Total Market Size of Usher Syndrome in the US (2020-2034)
• Figure 13: Total Market Size of Usher Syndrome by therapies in the US (2020-2034)
• Figure 14: Total Market Size of Usher Syndrome in EU4 and the UK (2020-2034)
• Figure 15: Total Market Size of Usher Syndrome by therapies in EU4 and the UK (2020-2034)
• Figure 16: Total Market Size of Usher Syndrome in Japan (2020-2034)
• Figure 17: Total Market Size of Usher Syndrome by therapies in Japan (2020-2034)
• Figure 18: Health Technology Assessment
• Figure 19: Reimbursement Process in Germany
• Figure 20: Reimbursement Process in France
• Figure 21: Reimbursement Process in Italy
• Figure 22: Reimbursement Process in Spain
• Figure 23: Reimbursement Process in the United Kingdom
• Figure 24: Reimbursement Process in Japan

Key Highlights:

• Usher Syndrome (USH) is the most common genetic condition responsible for combined loss of hearing and vision. Balance disorders and bilateral vestibular areflexia are also observed in some cases.
• Limited knowledge regarding pathophysiology, disease severity, and consequences is impeding the development of effective treatments for Usher Syndrome.
• People who have Usher Syndrome are born with it, but they usually get diagnosed as children or teenagers. There's no cure for Usher Syndrome, but treatments can help people manage their vision, hearing, and balance problems.
• Among the 7MM, the US accounted for the highest prevalent cases of Usher Syndrome in 2023, with around 21,000 cases; these cases are expected to increase during the forecast period.
• The market relies on off-label therapies that do not address Usher Syndrome's root cause. Patients depend on supportive care, including vitamin supplements, sunlight protection, and visual aids.
• Currently, Luxturna is the only approved therapy for retinal degeneration, which is a common feature of Usher Syndrome.
• In January 2020, the US FDA granted Rare Pediatric Disease (RPD) designation for QR-421a for the treatment of patients with mutations in exon 13 of the USH2A gene.
• In 2023, in the 7MM the total market size of Usher Syndrome was ~ USD 77 million.

DelveInsight's " Usher Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Usher Syndrome, historical and forecasted epidemiology as well as the Usher Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Usher Syndrome market report provides current treatment practices, emerging drugs, Usher Syndrome market share of the individual therapies, and current and forecasted Usher Syndrome market size from 2020 to 2034, segmented by seven major markets. The report also covers current Usher Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Usher Syndrome Disease Understanding and Treatment Algorithm

Usher Syndrome Overview

Usher Syndrome (USH) is the most common deaf-blind syndrome, with 50% of deaf-blindness in persons younger than 65 years of age. It is a genetic condition that includes hearing loss, retinopathy (retinitis pigmentosa), and vestibular areflexia with different entities and onset. It is an autosomal recessive disorder - passing from parents to children - that impacts three major senses in the body: vision, hearing and balance. Balance disorders and bilateral vestibular areflexia are also observed in some cases. USH has been grouped into three main clinical types: 1, 2, and 3, which are caused by mutations in different genes and are further divided into different subtypes.

Usher Syndrome Diagnosis

Diagnosis of Usher Syndrome involves pertinent questions regarding the person's medical history and testing of hearing, balance, and vision. A hearing (audiologic) exam measures the frequency and loudness of sounds that a person can hear. An electroretinogram measures the electrical response to the light-sensitive cells in the retina of the eyes. A retinal exam is done to observe the retina and other structures in the back of the eye. Vestibular (balance) function can be assessed by a variety of tests that evaluate different parts of the balance system. Genetic testing is clinically available for most of the genes associated with Usher Syndrome.

Further details related to diagnosis will be provided in the report.

Usher Syndrome Treatment

Presently, there is no cure for Usher Syndrome. Treatment involves managing hearing, vision, and balance problems. Some researchers have shown that taking a specific daily dose of vitamin A may slow the progression of retinal degeneration in some people with typical RP and Usher Syndrome type 2. Typically, treatment for hearing management includes hearing aids, assistive listening devices, cochlear implants, or other communication methods. Although some ophthalmologists believe that a high dose of vitamin A palmitate may slow, but not halt the progression of retinitis pigmentosa. Other treatments such as gene therapy, drug based therapy, artificial organ replacement are currently leading the market. Ongoing research on the Usher proteins function in auditory and visual cells will be important in determining the optimal target for gene replacement therapy.

Further details related to treatment will be provided in the report...

Usher Syndrome Epidemiology

The Usher Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of Usher Syndrome, diagnosed prevalent cases of Usher Syndrome, and type-specific cases of Usher Syndrome in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the US accounted for the highest prevalent cases of Usher Syndrome in 2023, with around 21,000 cases; these cases are expected to increase during the forecast period.
• Amongst EU4 and the UK, the total prevalent cases of Usher Syndrome were highest in Germany, while the lowest number of cases were in Spain in 2023.
• According to the estimates, in the US, it is observed that type 2 of Usher Syndrome was most prevalent type, accounting for over 60% of total cases in 2023.

Usher Syndrome Drug Chapters

The drug chapter segment of the Usher Syndrome report encloses a detailed analysis of the early-stage (Phase I/II and Phase I) and mid-stage (Phase II and Phase II/III) pipeline drug. The current key players for emerging drugs and their respective drug candidates include Nacuity Pharmaceuticals (NPI-001), Laboratoires Thea (Ultevursen). The drug chapter also helps understand the Usher Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Emerging Drugs

NPI-001: Nacuity Pharmaceuticals

NPI-001 is a differentiated, purified, prescription-quality, GMP-grade N-acetylcysteine amide (NACA) being developed to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels. In preclinical animal studies, NPI-001 preserved photoreceptor cells and functionality. A Phase I clinical trial of Nacuity's GMP-grade NPI-001 solution in healthy volunteers was completed with no serious adverse events. Currently, the company is investigating iptacopan in the Phase I/II trial (NCT04355689) for the treatment of patients with RP (retinitis pigmentosa) associated with Usher Syndrome.

Ultevursen: Laboratoires Thea

Ultevursen (formerly QR-421a) is a first-in-class investigational RNA therapy designed to address the underlying cause of vision loss in Usher Syndrome type 2a and non-syndromic USH due to mutations in exon 13 of the USH2A gene. QR-421a is designed to restore functional usherin protein by using an exon-skipping approach with the aim of stopping or reversing vision loss in patients. Ultevursen is intended to be administered through intravitreal injections in the eye and has been granted Orphan Drug Designation in the US and the European Union and received Fast Track and Rare Pediatric Disease Designations from the FDA. Currently, Ultevursen is being investigated in a Phase II/III trial, SIRIUS, for treating Usher Syndrome Type 2.

Drug Class Insight

Free radical scavenger

Free radical scavengers play a role in the treatment of Usher Syndrome by helping to reduce oxidative stress, which is implicated in the progression of the disease. Usher Syndrome is a genetic condition characterized by hearing loss and vision impairment, including retinitis pigmentosa. Research has shown that free radical scavengers, such as minocycline, nanoceria, and edaravone, possess antioxidant properties that can help reduce reactive oxygen species (ROS) levels and increase the expression of antioxidant-associated proteins in the retina. This can potentially contribute to the preservation of retinal function in conditions like retinitis pigmentosa, which is a major hallmark of Usher Syndrome.

Usher Syndrome Market Outlook

Currently, LUXTURNA (voretigene neparvovec) is the only approved therapy for Usher Syndrome and is only authorized for the treatment of a small subpopulation of patients that have the RPE65 mutation. There is currently no standard treatment for patients without the RPE65 mutation; therefore, most patients are limited to the best supportive care, including reliance on vitamin supplements, protection from sunlight, and visual aids. Only few key players are active in the pipeline such as Nacuity Pharmaceuticals and Laboratoires Thea for the treatment of Usher Syndrome.

Based on randomized clinical trials with vitamins and supplements, the only widely recommended treatment is supplementation with high-dose vitamin A palmitate and fish oil, along with avoidance of vitamin E, but these adjustments only delay degeneration. However, a comparison of seven clinical trials that measured visual acuity as a secondary outcome indicator showed that no significant difference was found in the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity with different doses of vitamin A and vitamin E in Usher Syndrome across treatment groups. Groups were either administered high-dose vitamin A, high-dose vitamin E, high-dose vitamin A and E, or trace amounts of both vitamins. This indicates that vitamin supplementation may have no beneficial effect in Usher Syndrome patients. Consequently, for most patients with Usher Syndrome, there is currently no cure or effective treatment to slow or stop disease progression.

The precise mechanism by which vitamin A supplementation provides its benefit is not known. It has been speculated that vitamin A rescues remaining cones, thereby explaining how one supplement may help a group of patients with different rod-specific gene defects. Vitamin E may lead to an adverse effect on the course of Usher Syndrome by inhibiting the absorption or transport of vitamin A.

Detailed market assessment will be provided in the final report.

Key Findings

• The total market size in the US for Usher Syndrome was estimated to be ~USD 45 million in 2023, which is expected to grow during the forecast period (2024-2034).
• The total market size in EU4 and the UK for Usher Syndrome was estimated to be nearly USD 30 million in 2023, which is expected to grow during the forecast period.
• In 2032, among the emerging therapies, the highest revenue was generated by Ultevursen, in the US.

Usher Syndrome Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034. The landscape of Usher Syndrome treatment has experienced a transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of retinal physicians, otolaryngologist, professionals, and the entire healthcare community in their tireless pursuit of advancing care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Usher Syndrome Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase II/III, Phase II. It also analyzes key players involved in developing targeted therapeutics. Companies like Nacuity Pharmaceuticals and Laboratoires Thea actively engage in mid stage research and development efforts for Usher Syndrome. The pipeline of Usher Syndrome possesses few potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2024-2034).

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Usher Syndrome emerging therapy.

Market Access and Reimbursement

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third-party organizations that provide services and educational programs to aid patients are also present.

The Centers for Medicare & Medicaid Services (CMS) agency within the US Department of Health and Human Services (HHS) administers the nation's major healthcare programs. The CMS oversees programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces. CMS collects and analyzes data, produces research reports, and works to eliminate fraud and abuse within the healthcare system.

Detailed market access and reimbursement assessment will be provided in the final report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of Usher Syndrome, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of mid-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Usher Syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive Usher Syndrome.

Usher Syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Usher Syndrome Pipeline Analysis
• Usher Syndrome Market Size and Trends
• Existing and Future Market Opportunity

Usher Syndrome Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Usher Syndrome Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Usher Syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

FAQs

• What was the Usher Syndrome market size, the market size by therapies, market share (%) distribution in 2023, and what would it look like by 2034? What are the contributing factors for this growth?
• What can be the future treatment paradigm for Usher Syndrome?
• What are the disease risks, burdens, and unmet needs of Usher Syndrome? What will be the growth opportunities across the 7MM concerning the patient population with Usher Syndrome?
• What are the current options for the treatment of Usher Syndrome? What are the current guidelines for treating Usher Syndrome in the 7MM?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
• What is the patient share in Usher Syndrome?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving Usher Syndrome.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis ranking of class-wise potential current and emerging therapies under the analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF USHER SYNDROME (USH)

4. USHER SYNDROME MARKET OVERVIEW AT A GLANCE

• 4.1. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF USHER SYNDROME IN 2020 IN THE 7MM
• 4.2. MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF USHER SYNDROME IN 2034 IN THE 7MM

5. KEY EVENTS

6. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

7. USHER SYNDROME: DISEASE BACKGROUND AND OVERVIEW

• 7.1. INTRODUCTION
• 7.2. GENETICS OF USH
  • 7.2.1. USH1
  • 7.2.2. USH2
  • 7.2.3. USH3
  • 7.2.4. Atypical Usher or Unclear Role
• 7.3. PROGNOSIS
• 7.4. SIGN AND SYMPTOMS
• 7.5. PATHOGENESIS
• 7.6. DIAGNOSIS
  • 7.6.1. Hearing Loss
  • 7.6.2. Balance
  • 7.6.3. Vision Loss
  • 7.6.4. Differential Diagnosis
  • 7.6.5. Diagnostic Algorithm
• 7.7. TREATMENT MANAGEMENT

8. EPIDEMIOLOGY AND PATIENT POPULATION

• 8.1. KEY FINDINGS
• 8.2. ASSUMPTIONS AND RATIONALE
• 8.3. TOTAL PREVALENT CASES OF USHER SYNDROME IN THE 7MM
• 8.4. THE UNITED STATES
  • 8.4.1. Total Prevalent Cases of Usher Syndrome in the US
  • 8.4.2. Type-specific Cases of Usher Syndrome in the United States
• 8.5. EU4 AND THE UK
  • 8.5.1. Total Prevalent Cases of Usher Syndrome in EU4 and the UK
  • 8.5.2. Type-specific Cases of Usher Syndrome in EU4 and the UK
• 8.6. JAPAN
  • 8.6.1. Total Prevalent Cases of Usher Syndrome in Japan
  • 8.6.2. Type-specific Cases of Usher Syndrome in Japan

9. PATIENT JOURNEY

10. MARKETED DRUGS

• 10.1. LUXTURNA: SPARKS THERAPEUTICS (ROCHE)/NOVARTIS
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestones
  • 10.1.3. Others Developmental Activities
  • 10.1.4. Clinical Developmental
    • 10.1.4.1. Clinical Trial Information
  • 10.1.5. Safety and Efficacy
  • 10.1.6. Product Profile

11. EMERGING DRUGS

• 11.1. KEY COMPETITORS
• 11.2. ULTEVURSEN: LABORATOIRES THEA
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
• 11.3. NPI-001: NACUITY PHARMACEUTICALS
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Development
    • 11.3.3.1. Clinical Trials Information
• 11.4. RESEARCH PROGRAM: DUAL ADENO-ASSOCIATED VIRUS BASED USHER SYNDROME TYPE 1B GENE THERAPY: AAVANTGARDE BIO
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Safety and Efficacy
• 11.5. AAV- USH1C: ODYLIA THERAPEUTICS
  • 11.5.1. Product Description
  • 11.5.2. Safety and Efficacy
• 11.6. AK-CLRN1: ELI LILLY AND COMPANY
  • 11.6.1. Product Description
  • 11.6.2. Other Developmental Activities
• 11.7. ATSN-301: ATSENA THERAPEUTICS
  • 11.7.1. Product Description
• 11.8. RESEARCH PROGRAM: GENE THERAPY: CLEARSIDE BIOMEDICAL
  • 11.8.1. Product Description

12. USHER SYNDROME: MARKET ANALYSIS

• 12.1. KEY FINDINGS
• 12.2. MARKET OUTLOOK
• 12.3. CONJOINT ANALYSIS
• 12.4. KEY MARKET FORECAST ASSUMPTIONS
• 12.5. TOTAL MARKET SIZE OF USHER SYNDROME IN THE 7MM
• 12.6. UNITED STATES MARKET SIZE
  • 12.6.1. Total Market Size of Usher Syndrome in the United States
  • 12.6.2. Market Size of Usher Syndrome by Therapies in the United States
• 12.7. EU4 AND THE UK MARKET SIZE
  • 12.7.1. Total Market Size of Usher Syndrome in EU4 and the UK
  • 12.7.2. Market Size of Usher Syndrome by Therapies in EU4 and the UK
• 12.8. JAPAN MARKET SIZE
  • 12.8.1. Total Market Size of Usher Syndrome in Japan
  • 12.8.2. Market Size of Usher Syndrome by Therapies in Japan

13. UNMET NEEDS

14. SWOT ANALYSIS

15. MARKET ACCESS AND REIMBURSEMENT

• 15.1. UNITED STATES
  • 15.1.1. Centre for Medicare & Medicaid Services (CMS)
• 15.2. EU4 AND THE UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. JAPAN
  • 15.3.1. MHLW
• 15.4. MARKET ACCESS AND REIMBURSEMENT OF USHER SYNDROME

16. APPENDIX

• 16.1. BIBLIOGRAPHY
• 16.2. REPORT METHODOLOGY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT